Arginine hydroxymethylbutyrate

Arginine Hydroxymethylbutyrate (HMB/Arginine Complex)

1. Identity and Chemical Characterization

1.1 Nomenclature and Chemical Identity

Arginine hydroxymethylbutyrate — also formally designated 3-hydroxy-3-methylbutyrate-L-arginine — is a salt formed by the conjugation of the leucine metabolite β-hydroxy-β-methylbutyrate (HMB) with the amino acid L-arginine. The chemical term HMB amino acid salt, for instance HMB-L-Arginine, refers to 3-hydroxy-3-methylbutyrate-L-arginine with a molecular weight of 292.33. This salt form represents one possible delivery vehicle for both active moieties simultaneously. In practice, however, the two ingredients — HMB and L-arginine — are most commonly co-administered as separate components within the same supplement formulation rather than as the discrete salt compound.

The HMB constituent carries several synonyms in the scientific and regulatory literature: β-hydroxy-β-methylbutyric acid, β-hydroxyisovalerate, 3-hydroxy-3-methylbutyrate, and, in some older texts, β-hydroxy-β-methylglutarate-CoA precursor. HMB is a five-carbon organic acid synthesized endogenously as a downstream metabolite of leucine — a branched-chain amino acid (BCAA) — through its catabolic pathway.

1.2 Natural Source and Endogenous Biosynthesis

HMB is synthesized in the human body through the metabolism of L-leucine, a branched-chain amino acid. In healthy individuals, approximately 60% of dietary L-leucine is metabolized after several hours, with roughly 5% (2–10% range) of dietary L-leucine being converted to HMB.

The biosynthetic pathway begins in skeletal muscle. The endogenous synthesis of HMB involves the conversion of leucine to α-ketoisocaproate, primarily in the skeletal muscle, in a reaction catalysed by the enzyme BCAA aminotransferase. The resulting α-ketoisocaproate is then converted to HMB in the liver by the enzyme ketoisocaproate dioxygenase. A parallel mitochondrial route directs α-KIC into the branched-chain keto-acid dehydrogenase (BCKAD) pathway, generating isovaleryl-CoA rather than HMB; in normal conditions, approximately 5% of leucine metabolism leads to endogenous synthesis of HMB, whereas a majority of KIC is converted to isovaleryl-CoA.

HMB is also present in trace amounts in certain foods. HMB is found in small quantities in foods such as grapefruit, alfalfa, and catfish. Since only a small fraction of HMB's metabolic precursor, L-leucine, is metabolized into HMB, pharmacologically active concentrations of the compound in blood plasma and muscle can only be achieved by supplementing HMB directly.

L-arginine, the partner constituent, is a semi-essential, conditionally essential amino acid. Arginine can be independently manufactured by the human body and does not need to be obtained directly through dietary intake. Arginine plays a significant role in healing, cell division, immune function, the elimination of ammonia from the body, and the release of hormones.

1.3 Common Forms and Preparations

Supplemental HMB is commercially available in two primary salt or acid forms. HMB is sold as an over-the-counter dietary supplement in the free acid form, β-hydroxy-β-methylbutyric acid (HMB-FA), and as a monohydrated calcium salt of the conjugate base, calcium β-hydroxy-β-methylbutyrate monohydrate (HMB-Ca, CaHMB). All of the studies published until 2011 utilized the calcium salt of HMB (HMB-Ca). Though most clinical studies of HMB have evaluated the effects of HMB-Ca, HMB-FA may provide a more efficient HMB delivery option.

Studies directly comparing pharmacokinetics of the two forms have yielded mixed results: HMB delivery by free acid gel results in a faster and greater peak in HMB plasma concentration as well as equally sustained concentration compared with CaHMB administered in a capsule. However, a more recent comparative study reached a different conclusion, finding superior bioavailability for the calcium salt form in its human sample.

In multi-ingredient clinical formulations combining HMB with arginine — and frequently also glutamine — the typical commercial presentation is an oral powder sachet dissolved in water. One commercially studied product (Juven^®, Abbott) and related formulations such as Heallagen^® and Abound^® have been used in clinical trials. Abound™ (Abbott, United States) is a specialized nutritional supplement containing l-glutamine, l-arginine, citric acid, and calcium HMB.

The HMB-L-arginine salt proper represents an additional formulation option. Possible alternative amino acid salts of HMB include the use of all essential and non-essential L-form, D-form, and DL-form amino acids and dipeptides such as HMB-Glycylarginine, HMB-Alanylarginine, and HMB-Alanylglutamine.

1.4 Discovery and Intellectual History

The metabolic origin of HMB was first characterized in 1988 when Nissen and colleagues investigated leucine metabolism, identifying HMB as a cleavage product derived from α-ketoisocaproic acid (α-KIC), with approximately 5% of dietary leucine undergoing conversion to HMB. The effects of HMB on human skeletal muscle were first discovered by Steven L. Nissen at Iowa State University in the mid-1990s. Nissen founded a company called Metabolic Technologies, Inc. (MTI) around the time of his discovery, which later acquired six HMB-related patents that the company has used to license the right to manufacture and incorporate HMB into dietary supplements.

2. Traditional and Historical Use

HMB, as a defined molecule identified through modern analytical chemistry, has no documented pre-modern ethnobotanical or traditional medical history as an isolated compound. It was not known as a discrete entity to any ancient or early modern medical tradition. Similarly, the specific arginine-HMB combination or the HMB-L-arginine salt carries no traditional use predating modern nutritional biochemistry.

However, HMB exists endogenously in all mammals that consume leucine-containing proteins, meaning that virtually every dietary tradition involving protein intake has involved low-level, unrecognized exposure to HMB as a metabolite. The foods most concentrated in HMB precursors — high-leucine proteins such as meat, fish, dairy, and legumes — have long featured in traditional diets globally, but this does not constitute intentional use of HMB.

L-arginine, individually, has been recognized as a constituent of dietary protein since the formal identification of amino acids in the 19th century; its supplemental use in clinical medicine and sports nutrition dates from the latter half of the 20th century. The deliberate combination of HMB with arginine as a therapeutic nutritional supplement emerged from research conducted in the 1990s and early 2000s in the context of HIV/AIDS-associated wasting and cancer cachexia, as detailed below.

3. Key Constituents and Mechanisms of Action

3.1 HMB: Proposed Mechanisms

HMB exerts its biological effects through multiple proposed, partially overlapping pathways. The scientific literature identifies three primary mechanisms:

3.1.1 Stimulation of the mTOR Signaling Pathway (Anabolic Mechanism)

HMB stimulates protein synthesis via mTOR, a protein kinase that has a central role in controlling mRNA translation efficiency. Activation of this pathway promotes protein synthesis through phosphorylation of downstream targets such as p70S6 kinase and 4E-BP1. The ergogenic effects of HMB supplementation are related to the enhancement of sarcolemma integrity, inhibition of protein degradation (ubiquitin pathway), decreased cell apoptosis, increased protein synthesis (mTOR pathway), stimulation of the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis, and enhancement of muscle stem cell proliferation and differentiation.

3.1.2 Inhibition of the Ubiquitin–Proteasome System (Anticatabolic Mechanism)

HMB's mechanisms of action are generally considered to operate through its capacity to stabilize the sarcolemma and/or attenuate proteolytic pathways. The role of HMB in stabilizing the sarcolemma is known as the Cholesterol Synthesis Hypothesis (CSH), while its antagonistic effects on proteolytic pathways appear to operate through the ubiquitin-proteasome dependent pathway (Ub-pathway). Evidence from cachectic cancer studies suggests that HMB may inhibit the ubiquitin-proteasome proteolytic pathway responsible for the specific degradation of intracellular proteins. Pre-clinical research has also demonstrated attenuation via the autophagy-lysosome system. Muscle protein breakdown is decreased by HMB via two major protein degradation pathways, the ubiquitin proteasome and the autophagy-lysosome systems.

3.1.3 The Cholesterol Synthesis Hypothesis (Membrane Stabilization)

HMB is metabolized intracellularly to HMG-CoA. HMG-CoA is then cleaved into acetyl-CoA and acetoacetate by HMG-CoA lyase or used in the production of cholesterol via the mevalonate pathway. A general hypothesis is that HMB is metabolized to HMG-CoA in tissues such as muscle, mammary tissue, and certain immune cells and is used for de novo cholesterol synthesis. Under catabolic stress or rapid cell growth, endogenous cholesterol synthesis may become rate-limiting, and HMB's provision of cytosolic HMG-CoA is proposed to support sarcolemmal integrity.

3.1.4 GH/IGF-1 Axis

Supplementation with HMB in several non-human animal species has been shown to increase the serum concentration of growth hormone and insulin-like growth factor 1 (IGF-1) via an unknown mechanism, in turn promoting protein synthesis through increased mTOR phosphorylation. Based upon limited clinical evidence in humans, supplemental HMB appears to increase the secretion of growth hormone and IGF-1 in response to resistance exercise.

Regarding the anticatabolic mechanism specifically, it is important to note that as of 2016, the signaling cascade that mediates the HMB-induced reduction in muscle protein breakdown has not been identified in living humans, although it is well-established that it attenuates proteolysis in humans in vivo.

3.2 L-Arginine: Mechanisms Relevant to the Combination

Arginine exerts its positive effects on the cardiovascular system through the production of nitric oxide, which increases blood flow and improves vascular damage. Arginine is required for the promotion of nitrogen balance, cell proliferation, T lymphocyte function, and collagen accumulation. It also converts into nitric oxide, which is known for its vasodilatory and angiogenic properties.

3.3 Synergistic Rationale

Oral intake of HMB, arginine, and glutamine may ameliorate muscle loss by stimulating protein synthesis and decreasing protein degradation while simultaneously decreasing inflammation. β-hydroxy-β-methylbutyrate is an active metabolite of the amino acid leucine that may improve muscle protein turnover. Arginine may synergise with HMB to attenuate muscle loss. Within triple-component formulations, although each component of the supplement has been shown to slow muscle proteolysis, HMB, the naturally occurring metabolite of the essential amino acid leucine, is considered the most active ingredient in the mixture and has been shown to stimulate protein synthesis, prevent proteolysis, and improve nitrogen balance in critically ill patients.

4. Scientific Evidence by Area of Use

4.1 HIV/AIDS-Associated Wasting

Among all clinical applications of the HMB/arginine combination, the strongest early evidence came from the HIV/AIDS-wasting context. Taking HMB by mouth, along with the amino acids arginine and glutamine, seems to increase body weight and lean body mass in people with AIDS when used for 8 weeks.

A key trial (Clark et al., 2000) — a randomized, double-blind, placebo-controlled study — examined HIV-positive patients with established AIDS. The study tested whether HMB and glutamine and arginine, compounds previously shown to slow muscle proteolysis, could synergistically alter the course of muscle wasting in patients with established acquired immunodeficiency syndrome (AIDS). Results showed significant increases in lean body mass in the active group.

A subsequent pooled safety and efficacy analysis (Rathmacher et al., 2004, JPEN, PMID: 15080599) examined the triple combination across three double-blind studies. Three double-blind studies examined the safety of the combination of HMB, arginine, and glutamine on blood chemistries, hematology, emotional profile, and adverse events. Study 1 was conducted in healthy adult males (n = 34), study 2 was in HIV patients with AIDS-associated weight loss (n = 43), and study 3 was in cancer patients with wasting (n = 32). Volunteers were assigned to either a placebo or a mixture of 3 g HMB, 14 g arginine, and 14 g glutamine per day. These results showed that HMB, arginine, and glutamine can be safely used to treat muscle wasting associated with AIDS and cancer.

Evidence assessment: Moderate-quality evidence from small-to-medium randomized controlled trials. Limitations include small sample sizes and, in most cases, concurrent antiretroviral therapy which acts as a confounding variable.

4.2 Cancer Cachexia

There is compelling evidence that HMB supplementation may be useful for clinical muscle wasting conditions including AIDS, cancer, bed-rest, and during periods of caloric deficits.

Early research (May et al., 2002, Am J Surg) showed that taking HMB by mouth, along with the amino acids arginine and glutamine, seems to increase body weight and lean body mass in people with cancer-related cachexia when used for 24 weeks.

The largest formal phase III test was the RTOG 0122 trial (Berk et al., 2008, PMID: 18293016), a randomized, double-blind, placebo-controlled study. Four hundred seventy-two advanced cancer patients with between 2% and 10% weight loss were randomized to a mixture of beta-hydroxyl beta-methyl butyrate, glutamine, and arginine or an isonitrogenous, isocaloric control mixture taken twice a day for 8 weeks. Lean body mass was estimated by bioimpedance and skin-fold measurements. Body plethysmography was used when available. Only 37% of the patients completed protocol treatment. Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend toward higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08). This trial was unable to adequately test the ability of beta-hydroxy-beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.

The NOURISH phase II trial (Pascoe et al., 2021, BMC Cancer, PMID: 34247580) subsequently evaluated HMB/Arg/Gln in patients with advanced lung cancer. NOURISH was a prospective, two-arm, open-label, multi-centre, randomised controlled phase II trial comparing cachexia in patients who received HMB/Arg/Gln with those who did not. All patients received structured nutritional, exercise, and symptom control. Conducted in five UK centres, patients aged >18 years with newly diagnosed advanced small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC) who were able to take oral nutrition, with a performance status of 0-to-2 and a life expectancy >4 months were eligible for trial entry.

Evidence assessment: Mixed. Smaller early studies suggested benefit in lean body mass. The largest phase III trial (RTOG 0122) was statistically inconclusive primarily due to a very high dropout rate. The NOURISH trial was phase II and designed primarily for feasibility. Evidence remains insufficient to establish a confirmed clinical benefit in cancer cachexia.

4.3 Sarcopenia and Muscle Loss in Aging

Studies were conducted to determine whether a mixture of specific nutrients — arginine and lysine, which support protein synthesis, and HMB, which can slow protein breakdown — could blunt the gradual loss of muscle that occurs in the elderly, thus improving strength and functionality.

Flakoll et al. (2004, Nutrition, PMID: 15105032), a double-blind, two-site study, enrolled women with a mean age of 76.7 years. Women were randomized to a placebo group (n = 23) or an experimental treatment group (2 g beta-hydroxy-beta-methylbutyrate, 5 g arginine, and 1.5 g lysine daily; n = 27). After 12 weeks, there was a 17% improvement in the "get-up-and-go" functionality test in the experimental group (-2.3 ± 0.5 s) but no change in the placebo group (0.0 ± 0.5 s; P = 0.002). These studies indicated that daily supplementation of HMB, arginine, and lysine for 12 weeks positively alters measurements of functionality, strength, fat-free mass, and protein synthesis, suggesting that the strategy of targeted nutrition has the ability to affect muscle health in elderly women.

Broader systematic evidence across HMB supplementation (with and without arginine) in older adults has been summarized in meta-analyses. Both regular exercise training and HMB supplementation are shown as effective treatments to delay or reverse frailty and reduce cognitive impairment in older people. However, in human studies, positive results were observed in chronic pulmonary disease, hip fracture, and in AIDS-related and cancer-related cachexia but not in rheumatoid cachexia, renal failure, and gastric bypass. Unfortunately, these clinical studies frequently used mixed supplements that contained various components including glutamine, arginine, leucine, higher caloric or protein content, and vitamins. This co-formulation issue makes attribution of benefit to any single component — including the HMB-arginine pair specifically — difficult.

Regarding trained versus untrained populations, evidence suggests a differential effect: HMB is particularly effective in untrained individuals who are exposed to strenuous exercise and in trained individuals who are exposed to periods of high physical stress. The low effectiveness of HMB in strength-trained athletes could be due to the suppression of the proteolysis that is induced by the adaptation to training, which may blunt the effects of HMB.

Evidence assessment: Moderate-quality evidence from multiple RCTs supporting modest improvements in lean body mass and functional outcomes in older adults when HMB is combined with arginine and/or lysine. Evidence is weaker for well-trained athletic populations.

4.4 Rheumatoid Cachexia

The triple-combination HMB/glutamine/arginine was tested in rheumatoid arthritis (RA) patients in a randomized controlled trial (Marcora et al., 2005, Clin Nutr, PMID: 15896432). Forty RA patients supplemented their diet with either HMB/GLN/ARG or a nitrogen- and calorie-balanced mixture of alanine, glutamic acid, glycine, and serine (placebo) for 12 weeks. Results showed that dietary supplementation with HMB/GLN/ARG was not superior to placebo in the treatment of rheumatoid cachexia (group × time interactions P > 0.05 for all outcomes). Dietary supplementation with HMB/GLN/ARG was better tolerated but not more effective in reversing cachexia in RA patients compared to the mixture of other non-essential amino acids used as placebo.

Evidence assessment: A single RCT showing no significant benefit over placebo in rheumatoid cachexia. Evidence is insufficient to support use in this condition.

4.5 Wound Healing and Pressure Ulcers

Multiple clinical investigations have tested HMB/arginine/glutamine combinations specifically for wound healing, with particular focus on pressure ulcers. Arginine's role in this context relates to its conversion to nitric oxide and its importance for collagen synthesis. The oral nutritional supplement was initially reported to improve wound healing via improved protein and collagen synthesis.

Wong et al. (2014, J Wound Care, PMID: 24810310) conducted a placebo-controlled trial. The study compared pressure ulcer healing rates in patients supplemented with a specialised amino acid mixture containing HMB, arginine, and glutamine alongside standard oral nutritional supplements, versus patients supplemented with oral nutritional supplements and a placebo mixture. Twenty-three inpatients with stage II, III, or IV pressure ulcers were randomised to receive (A) a HMB, arginine, and glutamine mixture twice daily alongside oral nutritional supplements (n = 11) or (B) standard nutritional care alongside oral nutritional supplements (n = 12) for 2 weeks. The proportion of viable tissues increased within 2 weeks on HMB, arginine, and glutamine supplementation (p = 0.02). PUSH scores showed significant improvement within 1 week of supplementation for the experimental group (p = 0.013). However, wound area alone did not decrease significantly in the short term for both groups.

A subsequent study examining long-term supplementation of HMB/Arg/Gln for pressure ulcers in sedentary older adults at geriatric rehabilitation centers reported dosages of 1.3 g HMB, 7.4 g Arg, 7.4 g Gln × 2/day; or 1.2 g HMB, 7.0 g Arg, 7.0 g Gln × 2/day; or 1.5 g HMB, 7.0 g Arg, 7.0 g Gln × 2/day (varying by protocol version).

One separate study found no improvement in late-stage pressure ulcer healing after 4 weeks of the arginine/glutamine/HMB formula. Use of a nutritional formula enriched with arginine, glutamine, and HMB does not improve late-stage pressure ulcer healing after 4 weeks.

Evidence assessment: Preliminary and mixed. Small sample sizes, short durations, and heterogeneous patient populations limit conclusions. Some studies suggest benefit in viability of wound tissue within weeks; others find no significant effect. Outcomes appear stage- and duration-dependent.

4.6 Perioperative and Cardiac Surgery Applications

Several trials have evaluated preoperative HMB/arginine/glutamine supplementation in cardiac surgery patients. A randomized controlled trial (PMID: 9375058) examined 70 patients. Participants were requested to consume 2 sachets of a combination of 7 g l-arginine, 7 g l-glutamine, and 1.5 g daily HMB or placebo 30 days before operation. Supplementation with these three amino acids was reported to be effective in wound healing, preventing cachexia, and increasing muscle mass in hypercatabolic individuals.

A secondary analysis of a randomised controlled trial focused on inflammatory markers in older patients (≥65 years) undergoing elective cardiac surgery. Patients were randomized to receive either HMB supplementation (1200 mg HMB, 7000 mg l-glutamine, and 7000 mg L-arginine, twice daily) or routine care for at least two weeks before surgery. It has been reported that Gln and Arg co-administration can decrease the production of proinflammatory cytokines.

Evidence assessment: Early-stage clinical evidence. Trials are generally small, single-center, and of varying methodological quality. No major guideline body currently recommends this specific combination as standard perioperative care.

4.7 Athletic Performance

There is conflicting evidence about the usefulness of HMB for weight training. Some research suggests that taking HMB by mouth, alone or along with other supplements, might increase strength, improve body composition, and reduce muscle damage when used during resistance training or intense endurance exercises. However, other research suggests that HMB does not improve these outcomes. The reason for the conflicting results is not entirely clear. There is some evidence that HMB might be more effective in people who are just beginning to train than in well-trained athletes.

The leucine metabolite beta-hydroxy-beta-methylbutyrate (HMB) has been extensively used as an ergogenic aid; particularly among bodybuilders and strength/power athletes, who use it to promote exercise performance and skeletal muscle hypertrophy. In endurance and martial arts athletes, HMB supplementation revealed positive effects on specific aerobic capacity variables.

Evidence assessment: Weak to moderate, with substantial heterogeneity. Evidence for benefit in untrained individuals undergoing resistance training is stronger than for well-trained athletes, where most rigorous studies show little to no meaningful additional benefit.

4.8 Cardiovascular Risk Markers

Several analyses have found potential lipid-related effects. The only consistent change in blood chemistry across animal and human studies was a decrease in LDL cholesterol, which changed 7% (P < .01). HMB appears to be safe, and may improve various markers of health, including blood pressure and LDL-cholesterol. These findings are preliminary and derive primarily from smaller observational components of exercise and supplementation trials rather than dedicated cardiovascular outcome studies.

4.9 Hormonal Effects

A 2024 systematic review and meta-analysis (PMC12224445) examined HMB's hormonal effects across 15 controlled trials comprising 712 participants. The studies evaluated the impact of HMB supplementation on hormonal outcomes, including testosterone, cortisol, insulin-like growth factor-1 (IGF-1), and growth hormone. Utilizing a random-effects model, the standardized mean differences (SMDs) and their corresponding 95% confidence intervals were computed, and the GRADE framework was applied.

Evidence assessment: Preliminary. The systematic review found some evidence of HMB's effect on testosterone, but evidence for IGF-1, cortisol, and growth hormone in humans remains inconclusive. Most hormonal data have been derived from animal studies or small human trials.

5. Body Systems and Health Areas

• Skeletal Muscle System: Muscle protein synthesis, anticatabolism, sarcopenia prevention, cachexia management — the most extensively studied domain.
• Immune System: The HMB/arginine/glutamine combination may also improve the way the immune system works in patients with wasting disease; and arginine is required for T lymphocyte function.
• Integument and Wound Healing: Tissue regeneration, collagen synthesis, pressure ulcer healing — via arginine's nitric oxide and collagen pathways and HMB's effects on protein turnover.
• Cardiovascular System: Potential LDL-cholesterol reduction, blood pressure effects, and nitric oxide-mediated vasodilation from arginine.
• Endocrine System: Preliminary evidence suggesting modulation of the GH/IGF-1 axis.
• Gastrointestinal Tract and Anastomosis: Animal studies have suggested potential benefit in the healing of intestinal anastomoses following surgery, though direct clinical trial data in humans are limited.

6. Dosage Forms and Dosages Reported in Studies

The following dosages reflect those specifically reported in published clinical research. These are descriptive of study protocols and do not constitute recommendations.

• HIV/AIDS wasting (Rathmacher et al., 2004): A mixture of 3 g HMB, 14 g arginine, and 14 g glutamine per day.
• Elderly women, muscle function (Flakoll et al., 2004): 2 g beta-hydroxy-beta-methylbutyrate, 5 g arginine, and 1.5 g lysine daily.
• Cardiac surgery preoperative (Cardiac RCT): 2 sachets of Heallagen® (a combination of 7 g l-arginine, 7 g l-glutamine, and 1.5 g daily HMB) daily for 30 days before operation.
• Cardiac surgery / anti-inflammatory secondary analysis: 1200 mg HMB, 7000 mg l-glutamine, and 7000 mg L-arginine, twice daily.
• Pressure ulcer wound healing (Wong et al., 2014): 7 g of Arginine, 7 g Glutamine and 1.2 g HMB twice a day.
• Pressure ulcer wound healing (geriatric retrospective, various protocols): 1.3 g HMB, 7.4 g Arg, 7.4 g Gln × 2/day; or 1.2 g HMB, 7.0 g Arg, 7.0 g Gln × 2/day; or 1.5 g HMB, 7.0 g Arg, 7.0 g Gln × 2/day.
• General HMB dosing across studies: Most studies have used 3 grams per day.
• Urinary excretion of HMB: The amount of HMB excreted in urine is dose-dependent. For low doses (1 g/day), the amount of HMB excreted is 14%, while for high doses (3 g/day), it is as much as 29%.

7. Safety Considerations and Interactions

7.1 General Safety Profile of HMB

Several studies indicated no adverse effects from HMB supplementation. It appears to be safe when taken over several months, with 3–6-g dosages in humans. It has no adverse effects on the hepatic enzyme function, lipid profile, renal function, or immune system.

A study in college-aged men reported no changes in liver enzymes, lipids, renal function, or immune system markers after 8 weeks of HMB supplementation. Although most studies report mild side effects (e.g., gastrointestinal discomfort) with HMB, other studies have reported no adverse effects.

Preclinical safety data: In a study conducted in compliance with Food and Drug Administration Good Laboratory Practice, rats consuming a diet of up to 5% HMB-Ca for 91 days did not exhibit any adverse effects vis-à-vis clinical observations, hematology, clinical chemistry, or organ weights. This study reported no-observed-adverse-effect levels (NOAEL) of 3.49 and 4.16 g·kg·BM^-1 for male and female rats, respectively.

7.2 Safety of the HMB/Arginine/Glutamine Triple Combination

The pooled safety analysis by Rathmacher et al. (2004) across three double-blind studies found that across the 3 studies, HMB, arginine, and glutamine supplementation was not associated with any adverse indicators of health. The only significant changes noted were positive indicators of health status. HMB, arginine, and glutamine supplementation was associated with an improvement in emotional profile (p = .05), a decreased feeling of weakness (p = .03), and increased red blood cells, hemoglobin, hematocrit, lymphocytes, and eosinophils (p < .05) when compared with placebo-supplemented subjects.

7.3 Blood Urea Nitrogen Elevation

A clinically relevant finding observed in safety analyses is an effect on nitrogen metabolism markers. Blood creatinine levels were not changed. However, blood urea nitrogen increased (p = .01) with HMB, arginine, and glutamine supplementation, which was possibly caused by the additional nitrogen consumed or the fact that ureagenesis is influenced by arginine and glutamine supplementation. This finding does not necessarily represent renal impairment but should be interpreted with appropriate clinical context, particularly in patients with pre-existing renal disease.

7.4 Renal and Hepatic Function in Cardiac Surgery Patients

No serious adverse events, such as serious renal or hepatic dysfunction, were recorded in the HMB group in the cardiac surgery perioperative trial. AST and ALT, as indicators of hepatic function, showed no significant differences between the groups at any time point, and all values remained within the normal range. A transient elevation in blood urea nitrogen was noted pre-surgically in the supplemented group but resolved postoperatively.

7.5 Glutamine-Related Contraindications in the Combination

When the HMB/arginine combination is administered in conjunction with glutamine (a frequent formulation), the glutamine component carries specific contraindications. Glutamine supplementation is contraindicated in patients with hepatic failure and chronic renal failure. Blood ammonia levels are of concern if the patient has liver disease. Patients with chronic renal insufficiency might have an altered metabolism of glutamine. Additionally, glutamine may be contraindicated for patients who are taking methotrexate because supplementation might inhibit renal clearance of the drug, resulting in increased plasma levels of the medication.

7.6 Long-Term Safety Data Gaps

Researchers have not studied the safety of long-term use of HMB in rigorous controlled trials extending beyond approximately one year. Most formal safety data derive from studies of weeks to months in duration.

7.7 Tolerability

The combination of HMB, arginine, and glutamine has been generally well tolerated across clinical trial populations. These results show that HMB, arginine, and glutamine can be safely used to treat muscle wasting associated with AIDS and cancer. The most commonly noted side effects in some studies include mild gastrointestinal symptoms such as stomach discomfort. In rare cases, people may experience stomach pain, constipation, or itching while taking HMB.

8. Evidence Limitations and Research Gaps

The body of clinical literature on arginine hydroxymethylbutyrate — and, more broadly, on HMB/arginine co-supplementation — faces several recurring methodological challenges:

• Multi-ingredient formulations: Clinical studies frequently used mixed supplements that contained various components including glutamine, arginine, leucine, higher caloric or protein content, and vitamins, making it impossible to isolate the contribution of any single constituent.
• Small sample sizes: Most positive studies involved fewer than 100 participants, limiting statistical power and generalizability.
• High dropout rates: In cancer cachexia populations, high dropout rates (e.g., only 37% completion in RTOG 0122) have prevented adequate testing of efficacy hypotheses.
• Variable populations: Trained athletes, untrained elderly adults, critically ill patients, and those with specific disease states may respond differently, and aggregating evidence across these populations is problematic.
• Short durations: Few trials extend beyond 24 weeks, leaving questions about long-term maintenance of any observed benefits or late-emerging safety signals unanswered.
• Lack of mechanistic confirmation in humans: Many proposed mechanisms rest largely on in vitro or animal data, with incomplete translation to confirmed human physiology.

References

• US Patent 6,812,249 — Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
• Rathmacher JA et al. Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters. JPEN 2004; PMID: 15080599
• Clark RH et al. Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. PMID: 10850936
• Berk L et al. A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). PMID: 18293016
• Pascoe J et al. Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer (NOURISH). BMC Cancer 2021. PMC8274132
• Flakoll P et al. Effect of beta-hydroxy-beta-methylbutyrate, arginine, and lysine supplementation on strength, functionality, body composition, and protein metabolism in elderly women. Nutrition 2004. PMID: 15105032
• Marcora S et al. Dietary treatment of rheumatoid cachexia with beta-hydroxy-beta-methylbutyrate, glutamine and arginine: a randomised controlled trial. Clin Nutr 2005. PMID: 15896432
• Wong A et al. The use of a specialised amino acid mixture for pressure ulcers: a placebo-controlled trial. J Wound Care 2014. PMID: 24810310
• Wilson JM et al. Effects of beta-hydroxy-beta-methylbutyrate (HMB) on exercise performance and body composition across varying levels of age, sex, and training experience: A review. PMC2245953
• Holeček M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions. PMC5566641
• Rondanelli M et al. Health Benefits of β-Hydroxy-β-Methylbutyrate (HMB) Supplementation in Addition to Physical Exercise in Older Adults: A Systematic Review with Meta-Analysis. PMC6769498
• Durkalec-Michalski K, Jeszka J, Podgórski T. Mechanism of Action and the Effect of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation on Different Types of Physical Performance — A Systematic Review. PMC6724588
• Wilson JM et al. International Society of Sports Nutrition Position Stand: beta-hydroxy-beta-methylbutyrate (HMB). PMC3568064
• Baier S et al. Oral Supplementation with Beta-hydroxy-beta-methylbutyrate, Arginine, and Glutamine Improves Lean Body Mass in Healthy Older Adults. PMC6314919
• Demir IE et al. Effects of the Oral Nutritional Supplement Containing Arginine, Glutamine, and HMB (Abound®) on Healing of Colonic Anastomoses in Rats. PMC4775590
• Mohebbi H et al. The effects of preoperative supplementation with a combination of HMB, arginine, and glutamine on inflammatory and hematological markers of patients with heart surgery: a randomized controlled trial. PMC8832784
• Supplementation with HMB, l-arginine, and l-glutamine: double-blind randomized placebo-controlled clinical trial in heart surgery patients. PMC9375058
• Impact of preoperative beta-hydroxy-beta-methylbutyrate, arginine, and glutamine supplementation on inflammation in patients with cardiac surgery. Journal of Cardiology 2025
• β-Hydroxy β-methylbutyric acid — Wikipedia (citing peer-reviewed primary sources)
• Systematic review and meta-analysis: HMB supplementation and testosterone/hormonal outcomes. PMC12224445
• β-hydroxy-β-methylbutyrate supplementation mitigates muscle atrophy induced by inactivity and protein deprivation. PMC12176917
• Physiological Benefits, Applications, and Future Directions of β-Hydroxy-β-Methylbutyrate (HMB) in Food and Health Industries. Foods 2025 (MDPI)
• Nissen S, Abumrad N. Nutritional role of the leucine metabolite β-hydroxy β-methylbutyrate (HMB). J Nutr Biochem 1997
• Examine.com — HMB: benefits, dosage, and side effects (evidence-based summary)
• Memorial Sloan Kettering Cancer Center — HMB integrative medicine monograph
• Fuller JC et al. Free acid gel form of HMB improves HMB clearance from plasma compared with the calcium HMB salt. British Journal of Nutrition 2011
• Long-term supplementation with HMB/Arg/Gln on pressure ulcer healing in sedentary older adults. Journal of Yeungnam Medical Science 2022